FibroBiologics has completed manufacturing of a third batch of CYWC628, an allogeneic fibroblast cell therapy for diabetic foot ulcers, positioning the company to complete its Phase 1/2 trial with interim efficacy data expected in Q3 2026. The therapy targets a major complication of diabetes where conventional wound healing approaches often fail, addressing both tissue regeneration and the chronic inflammatory environment that impairs healing in diabetic patients.
Key Points
- Third cGMP batch completed; sufficient supply for trial completion
- Topical fibroblast cell therapy designed to accelerate wound healing
- Interim efficacy data anticipated Q3 2026 from randomized trial
Longevity Analysis
Diabetic foot ulcers represent a cascade failure across multiple physiological domains—impaired circulation to tissues, compromised defense mechanisms that fail to resolve chronic inflammation, and regenerative capacity that has been disrupted by sustained hyperglycemia. A cell-based therapeutic that directly addresses tissue regeneration could alter the trajectory of diabetes-related complications, reducing amputation risk and improving functional longevity in a population where vascular and metabolic dysfunction interact to accelerate aging. The shift from pharmaceutical intervention toward cell-based repair reflects a maturation in how we approach chronic tissue damage: not by masking symptoms, but by restoring the body's capacity to repair itself.
Original published by LT Wire.